A Phase 2 interventional study of Apremilast and Placebo in Psoriatic Arthritis, sponsored by Amgen. Completed at 38 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-19.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.
Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 10th largest by enrollment, is the only one that started in 2007, is one of 2 in phase 2, and was the 1st registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
Tanta University · Sites in Egypt
Ages 18–70
Amgen
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 219 across the 17 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
21 studies in Arthritis, Psoriatic by Amgen: 1 open now, 1 under way, none of them phase 3. Of 20 finished, 13 (65%) have results posted.
Among the 21 studies in Arthritis, Psoriatic by Amgen, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2007, is one of 2 in phase 2, and was the 3rd registered.
Amgen’s Arthritis, Psoriatic studies by the year they started, since 2000.
2 of the studies testing apremilast in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07398651Tanta UniversityApremilast and Adalimumab in Psoriatic Arthritis Patients | 2026-12-30 |
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing apremilast in Arthritis, Psoriatic, from their registry updates:
Among Amgen’s 21 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.
Prior to the implementation of Amendment 1/UK3 the study consisted of 3 phases - pre-randomization up to 35 days, up to 84 days placebo-controlled treatment and a 28-day observational follow up. After the implementation of Amendment 1/UK3, the study consisted of 4 phases - pre-randomization up to 35 days, up to 84 days treatment in the placebo controlled treatment phase, up to 84 days treatment in the active treatment extension phase and a 28 day follow up. Participants who completed the treatment phase prior to implementation of amendment 1/UK3 did not have the option of entering the extension phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must meet the following laboratory criteria:
Exclusion Criteria:
History of any cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 40 mg apremilast orally once a day (QD) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 40 mg apremilast QD for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 40 mg QD thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.
Drug: Apremilast
Participants received 20 mg apremilast orally twice a day (BID) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 20 mg apremilast BID for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 20 mg BID thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.
Drug: Apremilast
Participants received matching placebo to apremilast orally BID for 12 weeks during the Treatment Phase. Participants who entered the Extension Phase were re-randomized on Day 85 to receive either 40 mg apremilast QD or 20 mg apremilast BID for 12 weeks.
Drug: Placebo
Capsules for oral administration
Also known as: CC-10004, Otezla®
Capsules for oral administration
Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12
A modified American College of Rheumatology 20% (ACR 20) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 20% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.
Time frame: Baseline and Week 12
Number of Participants With Adverse Events During the Treatment Phase
The severity of each adverse event (AE) was graded based upon the participant's symptoms according to National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE, Version 3.0), on a scale from 1 (Mild AE) to 5 (Death due to AE). Severe AEs are defined as NCI CTCAE grade 3 or higher. AEs related to study drug are those determined by the investigator as suspected to be related to study drug where a temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other medications, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event. A serious adverse event (SAE) is any AE which: - Resulted in death - Was life-threatening - Required inpatient hospitalization or prolongation of existing hospitalization - Resulted in persistent or significant disability/incapacity - Was a congenital anomaly/birth defect - Constituted an important medical event.
Time frame: 12 weeks
Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 12
A PsARC response is defined as improvement from Baseline in at least 2 of the following 4 measures, at least 1 of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures, according to the following: • At least 30% improvement in the 78 tender joint count, • At least 30% improvement in the 76 swollen joint count, • At least 20% improvement in the patient global assessment of disease activity, measured on a 100 mm visual analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • At least 20% improvement in the physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Participants with no post-baseline PsARC scores were considered non-responders.
Time frame: Baseline and Week 12
Percentage of Participants With a Modified ACR 50 Response at Week 12
A modified American College of Rheumatology 50% (ACR 50) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 50% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.
Time frame: Baseline and Week 12
Percentage of Participants With a Modified ACR 70 Response at Week 12
A modified American College of Rheumatology 70% (ACR 70) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 70% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.
Time frame: Baseline and Week 12
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response Based on Disease Activity Score (DAS28)-CRP(4) at Week 12
The DAS28 measures the severity of disease at a specific time. DAS28-CRP(4) is derived from the following 4 variables: • 28 tender joint count, (TJC; does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count (SJC) • C-reactive protein (CRP) • Patient's global assessment of disease activity (GH) according to the formula: DAS28-CRP(4) = 0.56\*√(TJC28) + 0.28\*(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2
Time frame: Baseline and Week 12
Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 12
The DAS28 measures the severity of disease at a specific time. DAS28-CRP(3) is derived from the following 3 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) according to the formula: DAS28-CRP(3) = \[0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.36\*ln(CRP+1)\] \* 1.10 + 1.15. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2
Time frame: Baseline and Week 12
Percentage of Participants With DAS28-CRP(4) Score of Mild Disease Activity or In Remission at Week 12
The DAS28-CRP(4) measures the severity of disease derived from the following 4 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28-CRP(4) scores range from 0 to 9.4, where higher scores indicate more disease activity. Mild disease severity is defined as a DAS28-CRP(4) score of ≤ 3.2. In remission is defined as a DAS28-CRP(4) score of ≤ 2.6.
Time frame: Week 12
Percentage of Participants With DAS28-CRP(3) Score of Mild Disease Activity or In Remission at Week 12
The DAS28-CRP(3) measures the severity of disease derived from the following 3 variables: • 28 tender joint count (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) DAS28-CRP(3) scores range from 0 to 9.4, where higher scores indicate more disease activity. Mild disease severity is defined as a DAS28-CRP(3) score of ≤ 3.2. In remission is defined as a DAS28-CRP(3) score of ≤ 2.6.
Time frame: Week 12
Number of Participants Who Withdrew Prematurely Due to Lack of Efficacy
The number of participants who withdrew prematurely from the treatment phase due to lack of efficacy, including flare of psoriasis, flare of psoriatic arthritis or worsening or not responding to study treatment.
Time frame: Baseline to Week 12
Number of Participants With Adverse Events Leading to a Dose Reduction
The number of participants who were dose reduced during the treatment phase due to adverse events.
Time frame: Baseline to Week 12
Maximal ACR Response During the Treatment Phase
The ACR-N index score was calculated for each participant at each time point in the study according to the following definition: ACR-N = the lowest of the following 3 values: - percent improvement from Baseline in the 76 swollen joint count, - percent improvement from Baseline in the 78 tender joint count - median percent improvement from Baseline in the following 5 measures ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. The maximal ACR-N for each participant during the 12-week treatment period was calculated, and represents the maximal ACR response achieved.
Time frame: ACR was measured at Baseline and Weeks 2, 4, 6, 8, 10, and 12
Time to ACR 20 Response During the Treatment Phase
The Kaplan-Meier estimates of time to ACR 20 response was calculated for participants who had an ACR 20 response at any time during the treatment phase.
Time frame: Baseline to Week 12
Time to ACR 50 Response During the Treatment Phase
The Kaplan-Meier estimates of time to ACR 50 response was calculated for participants who had an ACR 50 response at any time during the treatment phase.
Time frame: Baseline to Week 12
Time to ACR 70 Response During the Treatment Phase
The Kaplan-Meier estimates of time to ACR 70 response was calculated for participants who had an ACR 70 response at any time during the treatment phase.
Time frame: Baseline to Week 12
Change From Baseline in Dactylitis Severity Score at Week 12
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated on a scale from 0 (no dactylitis) to 3 (severe dactylitis). The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 60.
Time frame: Baseline and Week 12
Percentage of Participants With Enthesitis
Enthesitis is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Enthesitis is characterized by swelling, pain, and tenderness around the calcaneous, and occasionally by effusion in the bursa associated with this joint. The enthesitis assessment is an evaluation of inflammation at the insertions of the Achilles tendon into the calcaneous and of the plantar fascia into the calcaneous. Inflammation at 1 or more insertions on either the right or left side constituted a positive assessment.
Time frame: Baseline and Week 12
Time to Relapse of Psoriatic Arthritis During the Observational Follow-up Phase
Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Observation Phase in participants who received apremilast and achieved at least an ACR 20 at their Final Treatment Phase/Early Termination Visit. The time to relapse during the Observational Phase was calculated from the time of maximum ACR reduction and from the date of the Final Treatment Phase visit. Participants classified as responders who did not relapse were censored at the day of the last follow-up.
Time frame: From Week 12 to end of 28-day observational follow-up (1) and from the date of maximal ACR during the 12-week Treatment Phase until the end of the 28-day observational follow-up phase (2).
Number of Participants Who Relapsed During the Observational Follow-up Phase
Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Observation Phase in participants who received apremilast and achieved at least an ACR 20 at their Final Treatment Phase/Early Termination Visit.
Time frame: 28-day observational follow-up period following Week 12
Change From Baseline in Short Form 36 (SF-36) Summary Physical and Mental Component Scores at Week 12
The Medical Outcome SF 36-Item Health Survey, Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The summary physical health score included the following subscales: physical functioning, role-physical, bodily pain, and general health. The summary mental health score included other subscales: vitality, social functioning, role-emotional, and mental health. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10, where higher scores are associated with better functioning/quality of life. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale. A higher change from baseline indicates an improvement in better health results or functioning.
Time frame: Baseline and Week 12
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12
The DLQI is a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on participants' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Each question is answered on a scale from 0 (not at all) to 3 (very much). The total score ranges from 0 to 30 where a higher score indicates that a participant's dermatological condition has a greater impact on their daily life.
Time frame: Baseline and Week 12
Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
The HAQ-DI is a self-administered instrument consisting of 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item asks over the past week whether a particular task can be performed. For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). The eight category scores are averaged into an overall HAQ-DI score on a scale from zero (no disability) to three (completely disabled).
Time frame: Baseline and Week 12
Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 12
The FACIT-Fatigue is a 13 item self-administered questionnaire that assesses both the physical and functional consequences of fatigue based on recall during the past 7 days. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The total score ranges from 0 to 52 with higher scores representing less fatigue.
Time frame: Baseline and Week 12
Number of Participants With Adverse Events During the Extension Phase
The severity of each adverse event (AE) was graded based upon the participant's symptoms according to National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE, Version 3.0), on a scale from 1 (Mild AE) to 5 (Death due to AE). Severe AEs are defined as NCI CTCAE grade 3 or higher. AEs related to study drug are those determined by the investigator as suspected to be related to study drug where a temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other medications, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event. A serious adverse event (SAE) is any AE which: - Resulted in death - Was life-threatening - Required inpatient hospitalization or prolongation of existing hospitalization - Resulted in persistent or significant disability/incapacity - Was a congenital anomaly/birth defect - Constituted an important medical event.
Time frame: Weeks 12 to 24 (Extension Phase)
Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24
A PsARC response is defined as improvement from Baseline in at least 2 of the following 4 measures, at least 1 of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • At least 30% improvement in the 78 tender joint count, • At least 30% improvement in the 76 swollen joint count, • At least 20% improvement in the patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • At least 20% improvement in the physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Participants with missing data were considered non-responders.
Time frame: Baseline and Week 24
Percentage of Participants With a Modified ACR 20 Response at Week 24
A modified ACR 20 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 20% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1) and from Week 12 (Day 85). Participants with no post-baseline ACR scores were considered non-responders.
Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24
Percentage of Participants With a Modified ACR 50 Response at Week 24
A modified ACR 50 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 50% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1) and from Week 12 (Day 85). Participants with no post-baseline ACR scores were considered non-responders.
Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24
Percentage of Participants With a Modified ACR 70 Response at Week 24
A modified ACR 70 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 70% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1). Participants with no post-baseline ACR scores were considered non-responders.
Time frame: Baseline (Day 1) and Week 24
Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(4) at Week 24
The DAS28 measures the severity of disease at a specific time. DAS28-CRP(4) is derived from the following 4 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein • Patient's global assessment of disease activity according to the formula: DAS28-CRP(4) = 0.56\*√(TJC28) + 0.28\*(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2
Time frame: Baseline and Week 24
Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 24
The DAS28 measures the severity of disease at a specific time. DAS28-CRP(3) is derived from the following 3 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) according to the formula: DAS28-CRP(3) = \[0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.36\*ln(CRP+1)\] \* 1.10 + 1.15. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2
Time frame: Baseline and Week 24
Maximal ACR Response During the Extension Period
The ACR-N index score was calculated for each participant at each time point in the study according to the following definition: ACR-N = the lowest of the following 3 values: • percent improvement from Baseline in the 76 swollen joint count, • percent improvement from Baseline in the 78 tender joint count • median percent improvement from Baseline in the following 5 measures ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. The maximal ACR-N for each participant during the 12-week extension period was calculated, and represents the maximal ACR response achieved.
Time frame: ACR was measured at Baseline and Weeks 16, 20 and 24
Time to ACR 20 Response During the Study
Time to ACR 20 was measured from the first dose of apremilast to the first time a participant achieved an ACR 20 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 20 response were calculated for participants who had an ACR 20 response at any time during the study.
Time frame: Baseline to Week 24
Time to ACR 50 Response During the Treatment and Extension Phase
Time to ACR 50 response was measured from the first dose of apremilast to the first time a participant achieved an ACR 50 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 50 response were calculated for participants who had an ACR 50 response at any time during the study.
Time frame: Baseline to Week 24
Time to ACR 70 Response During the Treatment and Extension Phase
Time to ACR 70 response was measured from the first dose of apremilast to the first time a participant achieved an ACR 70 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 70 response were calculated for participants who had an ACR 70 response at any time during the study.
Time frame: Baseline to Week 24
Change From Baseline and Week 12 in Dactylitis Severity Score at Week 24
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated on a scale from 0 (no dactylitis) to 3 (severe dactylitis). The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 60. Change in the dactylitis severity score was assessed from Baseline (Day 1) and from Week 12 (Day 85).
Time frame: Baseline, Week 12 and Week 24
Percentage of Participants With Enthesitis in the Extension Phase
Enthesitis is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Enthesitis is characterized by swelling, pain, and tenderness around the calcaneous, and occasionally by effusion in the bursa associated with this joint. The enthesitis assessment is an evaluation of inflammation at the insertions of the Achilles tendon into the calcaneous and of the plantar fascia into the calcaneous. Inflammation at 1 or more insertions on either the right or left side constituted a positive assessment.
Time frame: Week 12 and Week 24
Time to Relapse of Psoriatic Arthritis After Extension Phase
Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Follow-up Phase in participants who achieved at least an ACR 20 at their Final Extension Phase (Week 24)/Early Termination Visit. The time to relapse during the Follow-up Phase was calculated from the time of maximum ACR reduction and from the date of the Final Extension Phase visit. Participants classified as responders who did not relapse were censored at the day of the last follow-up.
Time frame: From Week 24 to the end of the 28-day follow-up (1) and from the date of maximal ACR until the end of the 28-day follow-up phase (2).
Number of Participants Who Relapsed After the Extension Phase
Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Follow-up Phase in participants who achieved at least an ACR 20 at their Final Extension Phase/Early Termination Visit.
Time frame: Week 24 to Week 28 (28-day follow-up period)
Change From Baseline and Week 12 in SF-36 at Week 24
The Medical Outcome SF 36-Item Health Survey, Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The summary physical health score included the following subscales: physical functioning, role-physical, bodily pain, and general health. The summary mental health score included other subscales: vitality, social functioning, role-emotional, and mental health. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10, where higher scores are associated with better functioning/quality of life. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale. A higher change from baseline indicates an improvement in better health results or functioning.
Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24
Change From Baseline and Week 12 in Dermatology Life Quality Index (DLQI) at Week 24
The DLQI is a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on participants' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Each question is answered on a scale from 0 (not at all) to 3 (very much) The total score ranges from 0 to 30 where a higher score indicates that a participant's dermatological condition has a greater impact on their daily life.
Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24
Change From Baseline and Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24
The HAQ-DI is a self-administered instrument consisting of 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item asks over the past week whether a particular task can be performed. For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). The eight category scores are averaged into an overall HAQ-DI score on a scale from zero (no disability) to three (completely disabled).
Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24
Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 24
The FACIT-Fatigue is a 13 item self-administered questionnaire that assesses both the physical and functional consequences of fatigue based on recall during the past 7 days. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The total score ranges from 0 to 52 with higher scores representing less fatigue.
Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24
Participants were enrolled across 38 sites in Canada, Belgium, Germany, the Netherlands, and the United Kingdom.
| Milestone | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|---|
| Started | 46 | 40 | 0 | 20 | 20 |
| Completed | 35 | 36 | 0 | 19 | 13 |
| Not completed | 11 | 4 | 0 | 1 | 7 |
| Withdrew: Grade 2 or greater ae | 2 | 2 | 0 | 0 | 2 |
| Withdrew: Flare of psoriatic arthritis | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Worsening / not responding to study drug | 3 | 1 | 0 | 0 | 2 |
| Withdrew: Withdrew consent | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Other | 2 | 0 | 0 | 1 | 1 |
| Milestone | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|---|
| Started | 67 | 69 | 68 | 0 | 0 |
| Completed | 60 | 55 | 50 | 0 | 0 |
| Not completed | 7 | 14 | 18 | 0 | 0 |
| Withdrew: Grade 2 or greater adverse event (ae) | 3 | 4 | 2 | 0 | 0 |
| Withdrew: Aes not included in nci terminology | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Intolerability of the study drug | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Flare of psoriasis | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Flare of psoriatic arthritis | 0 | 3 | 3 | 0 | 0 |
| Withdrew: Worsening / not responding to study drug | 0 | 2 | 7 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 1 | 0 | 0 |
A modified American College of Rheumatology 20% (ACR 20) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 20% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12 | 35.8 | 43.5 | 11.8 |
The severity of each adverse event (AE) was graded based upon the participant's symptoms according to National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE, Version 3.0), on a scale from 1 (Mild AE) to 5 (Death due to AE). Severe AEs are defined as NCI CTCAE grade 3 or higher. AEs related to study drug are those determined by the investigator as suspected to be related to study drug where a temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other medications, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event. A serious adverse event (SAE) is any AE which: - Resulted in death - Was life-threatening - Required inpatient hospitalization or prolongation of existing hospitalization - Resulted in persistent or significant disability/incapacity - Was a congenital anomaly/birth defect - Constituted an important medical event.
| Participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| All adverse events | 58 | 59 | 55 |
| Adverse events related to study drug | 27 | 26 | 26 |
| Severe adverse events | 5 | 4 | 6 |
| Severe adverse events related to study drug | 1 | 1 | 1 |
| Serious adverse events | 0 | 4 | 4 |
| Serious adverse events related to study drug | 0 | 0 | 1 |
| Discontinued study drug due to adverse event | 6 | 10 | 7 |
| Discontinued due to AE related to study drug | 5 | 4 | 1 |
A PsARC response is defined as improvement from Baseline in at least 2 of the following 4 measures, at least 1 of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures, according to the following: • At least 30% improvement in the 78 tender joint count, • At least 30% improvement in the 76 swollen joint count, • At least 20% improvement in the patient global assessment of disease activity, measured on a 100 mm visual analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • At least 20% improvement in the physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Participants with no post-baseline PsARC scores were considered non-responders.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 12 | 50.7 | 52.2 | 22.1 |
A modified American College of Rheumatology 50% (ACR 50) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 50% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With a Modified ACR 50 Response at Week 12 | 13.4 | 17.4 | 2.9 |
A modified American College of Rheumatology 70% (ACR 70) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 70% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With a Modified ACR 70 Response at Week 12 | 7.5 | 5.8 | 1.5 |
The DAS28 measures the severity of disease at a specific time. DAS28-CRP(4) is derived from the following 4 variables: • 28 tender joint count, (TJC; does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count (SJC) • C-reactive protein (CRP) • Patient's global assessment of disease activity (GH) according to the formula: DAS28-CRP(4) = 0.56\*√(TJC28) + 0.28\*(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response Based on Disease Activity Score (DAS28)-CRP(4) at Week 12 | 49.3 | 55.1 | 38.2 |
The DAS28 measures the severity of disease at a specific time. DAS28-CRP(3) is derived from the following 3 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) according to the formula: DAS28-CRP(3) = \[0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.36\*ln(CRP+1)\] \* 1.10 + 1.15. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 12 | 50.7 | 44.9 | 44.1 |
The DAS28-CRP(4) measures the severity of disease derived from the following 4 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28-CRP(4) scores range from 0 to 9.4, where higher scores indicate more disease activity. Mild disease severity is defined as a DAS28-CRP(4) score of ≤ 3.2. In remission is defined as a DAS28-CRP(4) score of ≤ 2.6.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With DAS28-CRP(4) Score of Mild Disease Activity or In Remission at Week 12 | 38.8 | 33.3 | 23.5 |
The DAS28-CRP(3) measures the severity of disease derived from the following 3 variables: • 28 tender joint count (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) DAS28-CRP(3) scores range from 0 to 9.4, where higher scores indicate more disease activity. Mild disease severity is defined as a DAS28-CRP(3) score of ≤ 3.2. In remission is defined as a DAS28-CRP(3) score of ≤ 2.6.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Percentage of Participants With DAS28-CRP(3) Score of Mild Disease Activity or In Remission at Week 12 | 40.3 | 34.8 | 33.8 |
The number of participants who withdrew prematurely from the treatment phase due to lack of efficacy, including flare of psoriasis, flare of psoriatic arthritis or worsening or not responding to study treatment.
| Participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Number of Participants Who Withdrew Prematurely Due to Lack of Efficacy | 0 | 6 | 12 |
The number of participants who were dose reduced during the treatment phase due to adverse events.
| Participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Number of Participants With Adverse Events Leading to a Dose Reduction | 4 | 4 | 0 |
The ACR-N index score was calculated for each participant at each time point in the study according to the following definition: ACR-N = the lowest of the following 3 values: - percent improvement from Baseline in the 76 swollen joint count, - percent improvement from Baseline in the 78 tender joint count - median percent improvement from Baseline in the following 5 measures ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. The maximal ACR-N for each participant during the 12-week treatment period was calculated, and represents the maximal ACR response achieved.
| percent improvement | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Maximal ACR Response During the Treatment Phase | 22.3 ± 56.45 | 24.2 ± 37.63 | 10.7 ± 35.42 |
The Kaplan-Meier estimates of time to ACR 20 response was calculated for participants who had an ACR 20 response at any time during the treatment phase.
| days | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Time to ACR 20 Response During the Treatment Phase | 29.0 (29.0 to 43.0) | 30.0 (29.0 to 57.0) | 29.0 (20.0 to 47.0) |
The Kaplan-Meier estimates of time to ACR 50 response was calculated for participants who had an ACR 50 response at any time during the treatment phase.
| days | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Time to ACR 50 Response During the Treatment Phase | 43.0 (29.0 to 61.0) | 57.5 (56.0 to 72.0) | 15.0 (14.0 to 73.0) |
The Kaplan-Meier estimates of time to ACR 70 response was calculated for participants who had an ACR 70 response at any time during the treatment phase.
| days | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Time to ACR 70 Response During the Treatment Phase | 62.0 (47.0 to 85.0) | 57.0 (43.0 to 85.0) | 58.0 (31.0 to 85.0) |
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated on a scale from 0 (no dactylitis) to 3 (severe dactylitis). The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 60.
| units on a scale | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Change From Baseline in Dactylitis Severity Score at Week 12 | -0.9 ± 2.39 | -1.2 ± 3.11 | -0.2 ± 3.75 |
Enthesitis is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Enthesitis is characterized by swelling, pain, and tenderness around the calcaneous, and occasionally by effusion in the bursa associated with this joint. The enthesitis assessment is an evaluation of inflammation at the insertions of the Achilles tendon into the calcaneous and of the plantar fascia into the calcaneous. Inflammation at 1 or more insertions on either the right or left side constituted a positive assessment.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Achilles tendon into the calcaneous: Baseline | 22.4 | 21.7 | 35.3 |
| Achilles tendon into the calcaneous: Week 12 | 20.9 | 17.4 | 17.6 |
| Plantar fascia into the calcaneous: Baseline | 26.9 | 26.1 | 14.7 |
| Plantar fascia into the calcaneous: Week 12 | 19.4 | 21.7 | 17.6 |
Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Observation Phase in participants who received apremilast and achieved at least an ACR 20 at their Final Treatment Phase/Early Termination Visit. The time to relapse during the Observational Phase was calculated from the time of maximum ACR reduction and from the date of the Final Treatment Phase visit. Participants classified as responders who did not relapse were censored at the day of the last follow-up.
| days | Apremilast 40 mg QD | Apremilast 20 mg BID |
|---|---|---|
| 1. From Week 12 | 16.0 (15.0 to 29.0) | 15.0 (14.0 to 29.0) |
| 2. From Date of Maximal ACR Response | 43.0 (34.0 to 73.0) | 29.0 (22.0 to 43.0) |
Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Observation Phase in participants who received apremilast and achieved at least an ACR 20 at their Final Treatment Phase/Early Termination Visit.
| Participants | Apremilast 40 mg QD | Apremilast 20 mg BID |
|---|---|---|
| Number of Participants Who Relapsed During the Observational Follow-up Phase | 5 | 9 |
The Medical Outcome SF 36-Item Health Survey, Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The summary physical health score included the following subscales: physical functioning, role-physical, bodily pain, and general health. The summary mental health score included other subscales: vitality, social functioning, role-emotional, and mental health. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10, where higher scores are associated with better functioning/quality of life. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale. A higher change from baseline indicates an improvement in better health results or functioning.
| units on a scale | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Mental Component | 1.0 ± 8.01 | 3.4 ± 7.18 | -0.8 ± 8.39 |
| Physical Component | 2.1 ± 5.94 | 2.4 ± 7.89 | 0.8 ± 6.24 |
The DLQI is a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on participants' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Each question is answered on a scale from 0 (not at all) to 3 (very much). The total score ranges from 0 to 30 where a higher score indicates that a participant's dermatological condition has a greater impact on their daily life.
| units on a scale | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12 | -2.6 ± 5.96 | -1.8 ± 4.29 | -0.3 ± 4.82 |
The HAQ-DI is a self-administered instrument consisting of 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item asks over the past week whether a particular task can be performed. For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). The eight category scores are averaged into an overall HAQ-DI score on a scale from zero (no disability) to three (completely disabled).
| units on a scale | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | -0.2 ± 0.39 | -0.2 ± 0.35 | -0.1 ± 0.39 |
The FACIT-Fatigue is a 13 item self-administered questionnaire that assesses both the physical and functional consequences of fatigue based on recall during the past 7 days. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The total score ranges from 0 to 52 with higher scores representing less fatigue.
| units on a scale | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo |
|---|---|---|---|
| Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 12 | 4.3 ± 9.46 | 4.1 ± 8.78 | 0.5 ± 8.03 |
The severity of each adverse event (AE) was graded based upon the participant's symptoms according to National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE, Version 3.0), on a scale from 1 (Mild AE) to 5 (Death due to AE). Severe AEs are defined as NCI CTCAE grade 3 or higher. AEs related to study drug are those determined by the investigator as suspected to be related to study drug where a temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other medications, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event. A serious adverse event (SAE) is any AE which: - Resulted in death - Was life-threatening - Required inpatient hospitalization or prolongation of existing hospitalization - Resulted in persistent or significant disability/incapacity - Was a congenital anomaly/birth defect - Constituted an important medical event.
| Participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| All adverse events | 30 | 29 | 16 | 11 |
| Adverse events related to study drug | 12 | 8 | 4 | 4 |
| Severe adverse events | 5 | 3 | 3 | 4 |
| Serious adverse events | 2 | 3 | 1 | 1 |
| Serious adverse events related to study drug | 0 | 0 | 0 | 1 |
| Discontinued study drug due to adverse event | 3 | 2 | 0 | 3 |
| Discontinued due to AE related to study drug | 1 | 1 | 0 | 1 |
A PsARC response is defined as improvement from Baseline in at least 2 of the following 4 measures, at least 1 of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • At least 30% improvement in the 78 tender joint count, • At least 30% improvement in the 76 swollen joint count, • At least 20% improvement in the patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • At least 20% improvement in the physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Participants with missing data were considered non-responders.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24 | 26.1 | 20.0 | 55.0 | 40.0 |
A modified ACR 20 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 20% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1) and from Week 12 (Day 85). Participants with no post-baseline ACR scores were considered non-responders.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Response From Baseline | 43.5 | 42.5 | 45.0 | 40.0 |
| Response From Week 12 | 16.7 | 14.7 | 15.4 | 16.7 |
A modified ACR 50 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 50% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1) and from Week 12 (Day 85). Participants with no post-baseline ACR scores were considered non-responders.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Response From Baseline | 23.9 | 22.5 | 20.0 | 15.0 |
| Response From Week 12 | 9.7 | 5.9 | 15.4 | 5.6 |
A modified ACR 70 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 70% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1). Participants with no post-baseline ACR scores were considered non-responders.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Percentage of Participants With a Modified ACR 70 Response at Week 24 | 13.0 | 17.5 | 15.0 | 5.0 |
The DAS28 measures the severity of disease at a specific time. DAS28-CRP(4) is derived from the following 4 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein • Patient's global assessment of disease activity according to the formula: DAS28-CRP(4) = 0.56\*√(TJC28) + 0.28\*(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(4) at Week 24 | 67.4 | 60.0 | 70.0 | 50.0 |
The DAS28 measures the severity of disease at a specific time. DAS28-CRP(3) is derived from the following 3 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) according to the formula: DAS28-CRP(3) = \[0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.36\*ln(CRP+1)\] \* 1.10 + 1.15. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 24 | 60.9 | 67.5 | 65.0 | 55.0 |
The ACR-N index score was calculated for each participant at each time point in the study according to the following definition: ACR-N = the lowest of the following 3 values: • percent improvement from Baseline in the 76 swollen joint count, • percent improvement from Baseline in the 78 tender joint count • median percent improvement from Baseline in the following 5 measures ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. The maximal ACR-N for each participant during the 12-week extension period was calculated, and represents the maximal ACR response achieved.
| percent improvement | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Maximal ACR Response During the Extension Period | 29.1 ± 40.86 | 30.4 ± 36.77 | 23.3 ± 32.11 | 34.2 ± 31.16 |
Time to ACR 20 was measured from the first dose of apremilast to the first time a participant achieved an ACR 20 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 20 response were calculated for participants who had an ACR 20 response at any time during the study.
| days | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Time to ACR 20 Response During the Study | 43.0 (29.0 to 44.0) | 43.0 (29.0 to 59.0) | 34.0 (29.0 to 55.0) | 55.5 (29.0 to 57.0) |
Time to ACR 50 response was measured from the first dose of apremilast to the first time a participant achieved an ACR 50 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 50 response were calculated for participants who had an ACR 50 response at any time during the study.
| days | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Time to ACR 50 Response During the Treatment and Extension Phase | 71.0 (44.0 to 110.0) | 58.5 (56.0 to 86.0) | 84.5 (84.0 to 85.0) | 55.0 (23.0 to 57.0) |
Time to ACR 70 response was measured from the first dose of apremilast to the first time a participant achieved an ACR 70 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 70 response were calculated for participants who had an ACR 70 response at any time during the study.
| days | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Time to ACR 70 Response During the Treatment and Extension Phase | 138.0 (85.0 to 169.0) | 85.0 (57.0 to 141.0) | — | — |
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated on a scale from 0 (no dactylitis) to 3 (severe dactylitis). The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 60. Change in the dactylitis severity score was assessed from Baseline (Day 1) and from Week 12 (Day 85).
| units on a scale | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Change from Baseline | -0.4 ± 3.47 | -1.5 ± 3.13 | -1.8 ± 4.94 | 0.1 ± 1.08 |
| Change from Week 12 | 0.3 ± 3.07 | -0.2 ± 1.97 | -0.3 ± 0.98 | -0.8 ± 2.39 |
Enthesitis is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Enthesitis is characterized by swelling, pain, and tenderness around the calcaneous, and occasionally by effusion in the bursa associated with this joint. The enthesitis assessment is an evaluation of inflammation at the insertions of the Achilles tendon into the calcaneous and of the plantar fascia into the calcaneous. Inflammation at 1 or more insertions on either the right or left side constituted a positive assessment.
| percentage of participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Achilles tendon into the calcaneous: Week 12 | 17.4 | 15.0 | 20.0 | 20.0 |
| Achilles tendon into the calcaneous: Week 24 | 19.6 | 15.0 | 0.0 | 15.0 |
| Plantar fascia into the calcaneous:Week 12 | 15.2 | 17.5 | 25.0 | 10.0 |
| Plantar fascia into the calcaneous: Week 24 | 13.0 | 7.5 | 0.0 | 10.0 |
Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Follow-up Phase in participants who achieved at least an ACR 20 at their Final Extension Phase (Week 24)/Early Termination Visit. The time to relapse during the Follow-up Phase was calculated from the time of maximum ACR reduction and from the date of the Final Extension Phase visit. Participants classified as responders who did not relapse were censored at the day of the last follow-up.
| days | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| 1. From Week 12 | 31.0 (29.0 to NA) | 32.0 (29.0 to 38.0) | 16.0 (NA to NA) | 29.0 (15.0 to NA) |
| 2. From Date of Maximal ACR Response | 85.0 (57.0 to NA) | 111 (41.0 to NA) | 16.0 (NA to NA) | 29.0 (15.0 to NA) |
Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Follow-up Phase in participants who achieved at least an ACR 20 at their Final Extension Phase/Early Termination Visit.
| participants | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Number of Participants Who Relapsed After the Extension Phase | 8 | 8 | 1 | 2 |
The Medical Outcome SF 36-Item Health Survey, Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The summary physical health score included the following subscales: physical functioning, role-physical, bodily pain, and general health. The summary mental health score included other subscales: vitality, social functioning, role-emotional, and mental health. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10, where higher scores are associated with better functioning/quality of life. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale. A higher change from baseline indicates an improvement in better health results or functioning.
| units on a scale | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Mental Component: Change from Baseline | 0.2 ± 9.08 | 1.4 ± 8.92 | -2.7 ± 12.20 | -1.0 ± 14.00 |
| Mental Component: Change from Week 12 | -1.1 ± 8.14 | -2.4 ± 9.35 | -2.5 ± 10.60 | -3.4 ± 10.61 |
| Physical Component: Change from Baseline | 3.2 ± 6.68 | 4.4 ± 7.74 | 1.8 ± 9.50 | 4.2 ± 9.99 |
| Physical Component: Change from Week 12 | 0.3 ± 6.10 | 1.0 ± 6.60 | -0.1 ± 8.50 | 2.5 ± 7.81 |
The DLQI is a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on participants' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Each question is answered on a scale from 0 (not at all) to 3 (very much) The total score ranges from 0 to 30 where a higher score indicates that a participant's dermatological condition has a greater impact on their daily life.
| units on a scale | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Change from Baseline | -3.0 ± 7.36 | -1.5 ± 4.08 | -2.6 ± 4.78 | -1.9 ± 5.50 |
| Change from Week 12 | -0.0 ± 5.72 | -0.1 ± 3.54 | -1.2 ± 2.07 | -2.0 ± 6.25 |
The HAQ-DI is a self-administered instrument consisting of 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item asks over the past week whether a particular task can be performed. For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). The eight category scores are averaged into an overall HAQ-DI score on a scale from zero (no disability) to three (completely disabled).
| units on a scale | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Change from Baseline | -0.1 ± 0.45 | -0.2 ± 0.37 | -0.1 ± 0.61 | -0.2 ± 0.59 |
| Change from Week 12 | 0.0 ± 0.37 | -0.0 ± 0.23 | -0.0 ± 0.46 | -0.2 ± 0.44 |
The FACIT-Fatigue is a 13 item self-administered questionnaire that assesses both the physical and functional consequences of fatigue based on recall during the past 7 days. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The total score ranges from 0 to 52 with higher scores representing less fatigue.
| units on a scale | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo/Apremilast 40 mg QD | Placebo/Apremilast 20 mg BID |
|---|---|---|---|---|
| Change from Baseline | 4.4 ± 9.76 | 5.9 ± 7.76 | 1.3 ± 11.23 | 1.3 ± 12.34 |
| Change from Week 12 | -0.3 ± 8.56 | 0.1 ± 6.19 | -2.4 ± 9.05 | -1.3 ± 13.10 |
Collected over Adverse events are reported for the 12-week placebo-controlled phase, including AEs that occurred during the 28-day observational follow-up, and for up to 24 weeks for all participants who were randomized or re-randomized to apremilast at any time during the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Week 12: Apremilast 40 mg QD | — | 0/67 (0%) | 45/67 (67.2%) |
| Week 12: Apremilast 20 mg BID | — | 4/69 (5.8%) | 44/69 (63.8%) |
| Week 12: Placebo | — | 6/68 (8.8%) | 42/68 (61.8%) |
| Week 24: Apremilast 40 mg QD | — | 3/87 (3.4%) | 63/87 (72.4%) |
| Week 24: Apremilast 20 mg BID | — | 8/89 (9%) | 62/89 (69.7%) |
| Event | Week 12: Apremilast 40 mg QD | Week 12: Apremilast 20 mg BID | Week 12: Placebo | Week 24: Apremilast 40 mg QD | Week 24: Apremilast 20 mg BID |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/67 | 0/69 | 2/68 | 0/87 | 0/89 |
| VomitingGastrointestinal disorders | 0/67 | 0/69 | 1/68 | 0/87 | 0/89 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/67 | 0/69 | 1/68 | 0/87 | 0/89 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 0/67 | 0/69 | 1/68 | 0/87 | 0/89 |
| FallInjury, poisoning and procedural complications | 0/67 | 0/69 | 1/68 | 0/87 | 0/89 |
| Balance disorderNervous system disorders | 0/67 | 0/69 | 1/68 | 0/87 | 0/89 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/67 | 0/69 | 1/68 | 0/87 | 0/89 |
| Intervertebral disc degenerationMusculoskeletal and connective tissue disorders | 0/67 | 1/69 | 0/68 | 0/87 | 1/89 |
| Sinus tachycardiaCardiac disorders | 0/67 | 1/69 | 0/68 | 0/87 | 1/89 |
| Biliary colicHepatobiliary disorders | 0/67 | 1/69 | 0/68 | 0/87 | 1/89 |
| Event | Week 12: Apremilast 40 mg QD | Week 12: Apremilast 20 mg BID | Week 12: Placebo | Week 24: Apremilast 40 mg QD | Week 24: Apremilast 20 mg BID |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 18/67 | 14/69 | 7/68 | 23/87 | 14/89 |
| NasopharyngitisInfections and infestations | 8/67 | 8/69 | 14/68 | 23/87 | 18/89 |
| NauseaGastrointestinal disorders | 15/67 | 12/69 | 10/68 | 23/87 | 14/89 |
| HeadacheNervous system disorders | 15/67 | 13/69 | 11/68 | 17/87 | 17/89 |
| FatigueGeneral disorders | 11/67 | 6/69 | 6/68 | 11/87 | 7/89 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 5/67 | 7/69 | 8/68 | 10/87 | 13/89 |
| DizzinessNervous system disorders | 7/67 | 3/69 | 3/68 | 7/87 | 3/89 |
| Abdominal pain upperGastrointestinal disorders | 4/67 | 7/69 | 3/68 | 5/87 | 8/89 |
| MigraineNervous system disorders | 2/67 | 6/69 | 0/68 | 3/87 | 6/89 |
| PruritusSkin and subcutaneous tissue disorders | 5/67 | 2/69 | 1/68 | 5/87 | 4/89 |
| Age, Continuous(years) | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 49.9 ± 11.17 | 50.9 ± 12.58 | 51.1 ± 10.80 | 50.6 ± 11.50 |
| Sex: Female, Male(Participants) | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo | Total |
|---|---|---|---|---|
| Female | 35 | 26 | 36 | 97 |
| Male | 32 | 43 | 32 | 107 |
| Race/Ethnicity, Customized(Participants) | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo | Total |
|---|---|---|---|---|
| White | 62 | 67 | 68 | 197 |
| Black | 1 | 0 | 0 | 1 |
| Hispanic | 1 | 0 | 0 | 1 |
| Asian/Pacific Islander | 2 | 1 | 0 | 3 |
| American Indian/Alaska Native | 0 | 0 | 0 | 0 |
| Other | 1 | 1 | 0 | 2 |
| Psoriatic Arthritis Disease Category(Participants) | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo | Total |
|---|---|---|---|---|
| Asymmetrical Oligoarthritis | 26 | 21 | 20 | 67 |
| Predominant Spondylitis | 4 | 3 | 2 | 9 |
| Symmetric Polyarthritis | 32 | 36 | 39 | 107 |
| Arthritis Mutilans | 2 | 0 | 5 | 7 |
| Predominant Distal Interphalgeal Involvement | 2 | 9 | 2 | 13 |
| Missing/Unknown | 1 | 0 | 0 | 1 |
| Duration of Psoriatic Arthritis(years) | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 7.6 ± 8.73 | 8.4 ± 9.77 | 7.3 ± 6.74 | 7.8 ± 8.48 |
| Pain/Tender Joint Score(joints) | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 23.2 ± 17.63 | 20.6 ± 15.90 | 21.3 ± 15.55 | 21.7 ± 16.33 |
| Swollen Joint Score(joints) | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.4 ± 4.94 | 10.6 ± 9.88 | 9.5 ± 9.68 | 9.5 ± 8.51 |
| Psoriasis Severity(Participants) | Apremilast 40 mg QD | Apremilast 20 mg BID | Placebo | Total |
|---|---|---|---|---|
| None | 2 | 7 | 12 | 21 |
| Mild | 41 | 47 | 40 | 128 |
| Moderate | 20 | 15 | 11 | 46 |
| Severe | 4 | 0 | 5 | 9 |
2 further baseline measures are reported on the registry.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Mar 2007 to primary completion in May 2009, 26 months.
Results were first posted in Oct 2019, 10 years 5 months after primary completion. A results delay was requested in Mar 2013.
Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 26 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast